arwr – Scalper1

Arrowhead Hits Target In Hepatitis B Drug Trial

Beleaguered biotech stock Arrowhead Research (ARWR) gapped up sharply Thursday morning after the company reported positive midstage trial data on its hepatitis B drug candidate. Arrowhead kicked off its analyst day by releasing top-line data from its phase-two trial of its drug ARC-520 in patients who tested positive for the hepatitis B virus E-antigen (HBeAg), a kind of antigen that the virus produces to resist the body’s immune system. Patients

Arrowhead Surges As Analysts Laud Hepatitis B Drug

Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched coverage at outperform with a price target of 35. His move came a day after Arrowhead received FDA permission to launch a phase 2a trial of hepatitis B drug ARC-520, which Yee believes could eventually